

POSTER PRESENTATION

Open Access

T lymphocyte engineering with cytokine nanogels for enhanced cancer immunotherapy

Li Tang*, Yiran Zheng, Llian Mabardi, Darrell J Irvine

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Background

Adoptive cell transfer (ACT) with autologous tumor-reactive T cells is a promising strategy in cancer immunotherapy, but treatment of solid tumors is limited by the rapid decline in function of the transplanted T cells. In order to maintain high numbers of viable antigen-specific cytotoxic T cells in tumors, co-administration of supporting immunostimulant agents together with transferred cells is often necessary in clinical practice. However, the high systemic doses of such agents needed to enhance T cell functionality can also result in serious side effects.

Methods

Here, we developed a carrier-free strategy to deliver cytokines specifically to adoptively transferred T cells for cancer immunotherapy. IL-2-Fc or an IL-15 superagonist were chemically cross-linked with a disulfide linker to form protein nanogels (NGs), which were conjugated to the plasma membrane of ACT T cells.

Results

These NGs had exceptionally high loading of cytokines (~70 wt%) and released native protein in physiological conditions in a sustained manner through breakdown of the degradable disulfide linker in response to the activated T cell surface reduction activity. Cytokine-NGs were chemically conjugated onto the plasma membrane of donor T cells, enabling continuous pseudo-autocrine release of cytokine for stimulation of transferred CD8⁺ T cells. Transferred pmel-1 CD8⁺ T cells with optimized number of NGs conjugated per cell showed enhanced expansion and long persistence in B16F10 tumor bearing mice. Quantification of transferred Thy1.1+CD8⁺ T cells in tumors at Day 13 showed that T cells with conjugated cytokine-NGs expanded ~80

fold more than the T cells with systemically administered free cytokine.

Conclusions

We demonstrated that the cytokine-NG-T cell conjugation strategy could augment transferred T cell expansion efficiently and specifically *in vivo*, and thus improve the therapeutic efficacy. This T cell-NG “back pack” approach provides a readily generalizable strategy to provide auto-crine protein drug support to donor cells to enhance the safety and efficacy of ACT.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P54

Cite this article as: Tang et al.: T lymphocyte engineering with cytokine nanogels for enhanced cancer immunotherapy. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P54.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Massachusetts Institute of Technology, Cambridge, MA, USA



© 2015 Tang et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.